The rate is falling. The death toll is climbing. Both things are true at once, and that contradiction sits at the heart of a new national reckoning with mesothelioma, the rare and brutal cancer that asbestos leaves behind. Pull up the numbers from 1990 and lay them beside 2023 and you would be forgiven for thinking the story was one of slow victory. Age-standardised incidence down by a third. Mortality down by nearly as much. A textbook regulatory success, decades in the making.
Except the bodies tell a different story. Over those same 33 years, the number of Americans diagnosed each year rose from 2,094 to 2,675, and annual deaths climbed from 1,981 to 2,591. More people, not fewer.
That paradox is the spine of a sweeping new analysis from Sylvester Comprehensive Cancer Center at the University of Miami, published in JCO Global Oncology. Drawing on Global Burden of Disease estimates for all 50 states, the team tracked incidence, mortality, disability and occupational risk across three decades, and what they found is a disease that refuses to behave like the relic everyone assumes it is. “Mesothelioma behaves like a time capsule,” says Chinmay Jani, chief fellow at Sylvester and co-lead author. “What we’re seeing today reflects exposures that happened 30 or 40 years ago, and in some cases, exposures that are still happening in quieter, less visible ways.” The latency is the trap. A fibre breathed in during the Nixon administration can sit dormant in the lining of the lung for forty years before anyone knows it’s there.
So how do the rates drop while the count rises? The arithmetic is grimly simple. The American population has grown and greyed, and a shrinking rate applied to a larger, older base still yields more cases.
The researchers put a number on the human cost using disability-adjusted life-years, a metric that folds together years lost to early death and years lived in poor health. By that measure the burden rose 14 per cent since 1990, even as the age-standardised rate fell by 40. “Declining rates don’t necessarily mean fewer lives affected,” says Kyle Edwards, co-lead author and an MD/MPH student at the Miller School of Medicine. “When you look at absolute numbers and disability, mesothelioma remains a substantial public health problem.”
The Widening Gap Between Men and Women
Dig into the figures by sex and the picture splits clean in two. Among men, incidence and mortality fell sharply, by more than 40 per cent, as the generations who built ships and packed insulation aged out of the data. Among women, the decline all but vanished: a 6.5 per cent dip in incidence that the statistics can’t even call real. Worse, female incidence actually rose in 20 states, and female deaths in 18, with the steepest recent climbs in places like South Dakota, Iowa and Mississippi. Female cases nationally jumped 64 per cent in absolute terms.
Why the divergence? Because for many women, the classic exposure story simply doesn’t apply. “For women, mesothelioma often doesn’t come with a neat occupational history,” says Estelamari Rodriguez, who leads thoracic oncology clinical research at Sylvester. Environmental fibres, asbestos carried home on a husband’s work clothes (para-occupational exposure can raise risk as much as tenfold), and the legacy material still lurking in schools, homes and public buildings all loom larger. A 1980 federal assessment reckoned roughly 250,000 teachers and school staff, a workforce that skews heavily female, were regularly exposed to asbestos-containing materials.
A Patchwork, Not a Gradient
Geography matters here in a way it rarely does for cancer. Maine, Alaska, Washington and Minnesota carried the heaviest burdens in 2023, and each carries it for its own reasons. Shipyards line the coasts of Maine and Washington. Minnesota’s toll traces back to the taconite iron ore miners of its Iron Range, who faced a nearly threefold higher risk from the asbestos-like fibres they disturbed. Alaska, oddly, has asbestos occurring naturally in the ground, kicked loose whenever the soil is broken for construction. The map of American mesothelioma looks less like a smooth gradient and more like a quilt stitched from local industry and geology. “Mesothelioma is a geographic disease,” Jani says. “State-level data allow us to see where prevention, remediation and surveillance efforts are most urgently needed.”
And then there is the finding that hasn’t moved at all. The mortality-to-incidence ratio, a rough population-level stand-in for survival, has hovered near 1 for the entire study period, edging from 0.93 to 0.95. In plain terms: almost everyone diagnosed still dies of the disease. Even immune checkpoint inhibitors, the much-heralded therapies approved since 2020, have yet to bend the national curve. Roughly 23 per cent of patients survive five years, and that’s with localised disease. “From a patient’s perspective, this is the hardest message,” says Gilberto Lopes, Sylvester’s chief of medical oncology. “Despite all our scientific advances, mesothelioma remains one of the most lethal solid tumors.”
What makes all of this so bitter is that nearly all of it was avoidable. In 2023, 95.7 per cent of US mesothelioma deaths traced back to occupational asbestos exposure, a fraction that has barely budged since 1990. American asbestos consumption has cratered, from a 1973 peak of 803,000 metric tons to under 520 tons today, yet the country has never enacted a full ban, and the fibres already woven into its older buildings, ships and infrastructure aren’t going anywhere. The authors argue the only way forward runs on two tracks at once: relentless remediation of that legacy material, and serious investment in treatments that actually work. “Mesothelioma reminds us that prevention and treatment are inseparable,” Lopes says. “We have to keep people from being exposed in the first place, while also doing better for those who are diagnosed.”
For clinicians, the takeaway is uncomfortable and specific: stop assuming a patient without a shipyard on their resume is in the clear, especially if she’s a woman in a high-burden state. For everyone else, mesothelioma is a reminder that some debts come due slowly. The fibre inhaled today may not announce itself until the 2060s, which means the shape of this disease decades from now is being written, quietly, right now.
Frequently Asked Questions
If asbestos has been regulated for decades, why are mesothelioma deaths still rising?
The disease has an unusually long latency, often more than 40 years between exposure and diagnosis, so today’s cases reflect exposures from the 1970s and 80s. On top of that, while the rate of disease has fallen, the US population has grown and aged, so a smaller rate applied to a larger base still produces more cases and deaths than before.
Why is mesothelioma becoming more of a women’s disease?
Men’s rates have dropped steeply as the heavily exposed shipbuilding and construction generations aged out, but women’s rates have barely moved and rose outright in 20 states. Researchers point to non-occupational pathways: environmental asbestos, fibres carried home on a family member’s clothes, and legacy material in schools and public buildings, none of which leave the tidy occupational history clinicians traditionally look for.
Does where you live really change your risk?
Considerably. States like Maine, Alaska, Washington and Minnesota top the burden charts for reasons ranging from shipyards to iron ore mining to naturally occurring asbestos in the soil. National averages tend to mask these concentrated, place-based risks, which is why the researchers argue surveillance and remediation should be targeted state by state.
Have new immunotherapy treatments improved survival?
Not yet at a population level. Immune checkpoint inhibitors entered practice after 2020, but the mortality-to-incidence ratio has stayed near 1 for three decades, meaning most people diagnosed still die of the disease. Only around 23 per cent of patients survive five years even when the cancer is caught while still localised.
The full study is available in JCO Global Oncology.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.